- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03879512
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Autologous Dendritic Cells and Metronomic Cyclophosphamide in Combination With Checkpoint Blockade for Relapsed High-Grade Gliomas in Children and Adolescents
This phase I/II trials evaluates the feasibility, safety and efficacy of an individualized cancer vaccine, based on autologous, tumor-lysate loaded dendritic cells in children and adolescents with relapsed high-grade gliomas. In addition, regulatory T cells are depleted by a short cycle of metronomic cyclophosphamide upfront of the vaccine in order to facilitate induction of immune responses.
Therapeutic DC vaccines are followed by four cycles of Nivo/Ipi double checkpoint blockade and a Nivolumab monotherapy maintenance in order to optimize the induced T-cell response.
Study Overview
Status
Conditions
Detailed Description
Relapsed high-grade gliomas (in the following addressed as high-grade gliomas = HGG) in children and adolescents represent a very bad prognosis group for which a recommended standard salvage therapy is currently not available.
Combination of Dendritic Cell (DC) vaccination, metronomic cyclophosphamide, and checkpoint blockade will be investigated in the present trial as a new treatment strategy for these patients: metronomic cyclophosphamide has been shown to significantly reduce numbers of regulatory T cells (Treg) without inducing general leukopenia. DCs might induce tumour-directed immune responses thereby facilitating long-term remissions. Efficacy of primed T-cell responses by the vaccine will potentially be enhanced by the application of checkpoint inhibitors Nivolumab (antiPD-L1) and Ipilimumab (antiCTLA4) in the post-vaccine phase and during maintenance.
Cyclophosphamide is an established drug used as an anti-cancer or immunosuppressive substance since decades, with extensive experience when used in low, non-myeloablative dosages. DCs represent an innovative new strategy in cellular immunotherapy. DCs in cancer patients have been used in a number of smaller studies, and in some of these trials, promising results could be obtained. Several studies showed a trend towards a prolonged overall survival with a few long-term survivors which is otherwise extremely rare in this high-risk population. Results seemed to be more favourable in pediatric than in adult patients. Checkpoint inhibitors (antiPD-L1 and/or antiCTLA4) have been shown to exhibit synergistic effects with vaccines in preclinical models, and prelimnary data of several early stage trials have shown promising results. Therefore, our study aims to improve the efficacy of a DC-based therapeutic vaccine by optimizing the conditions upfront of the vaccine (Treg depletion) and improving T-cell responses by checkpoint blockade after the vaccine in the effector phase.
In conclusion, this study will exploit the optimal efficacy of a therapeutic vaccine in children and adolescents with relapsed HGG.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Matthias Eyrich, MD
- Phone Number: 27728 +49-931-201
- Email: eyrich_m@ukw.de
Study Contact Backup
- Name: Paul G Schlegel, MD
- Phone Number: 27915 +49-931-201
- Email: schlegel_p@ukw.de
Study Locations
-
-
Bavaria
-
Würzburg, Bavaria, Germany, D-97080
- Recruiting
- University Children's Hospital
-
Contact:
- Matthias Eyrich, MD
- Phone Number: +49-931-201-27728
- Email: eyrich_m@ukw.de
-
Contact:
- Paul G Schlegel, MD
- Phone Number: +49-931-201-27915
- Email: schlegel_p@ukw.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of relapsed high-grade malignant glioma confirmed by central neuropathological and neuroradiological review (last magnetic resonance imaging diagnosis not older than 4 weeks) - including glioblastoma multiforme (WHO IV), anaplastic astrocytoma World Health Organization (WHO III), anaplastic oligodendroglioma (WHO III), anaplastic oligoastrocytoma (WHO III), anaplastic pilocytic astrocytoma (WHO III), anaplastic ganglioglioma (WHO III), anaplastic pleomorphic xanthoastrocytoma (analogous to WHO III), giant cell glioblastoma (WHO IV), and gliosarcoma (WHO IV) relapsed after first-line therapy.
- Patients aged 3 years and older but under 21 years at time of relapse diagnosis
- Written informed consent of the patient (mandatory from 14 years of age) or the parents (mandatory till 18 years of age).
- Prospect of resection of relapse tumour by neurosurgery (total, subtotal or partial)
Exclusion Criteria:
- Known hypersensitivity or contraindication to cyclophosphamide
- Known hypersensitivity or contraindications to Nivolumab or Ipilimumab.
- Other malignancies, either simultaneous or within the last 2 years
- Active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Pregnancy and / or lactation
- Patients who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile)
- Current or recent (within 4 weeks prior to start of trial treatment) treatment with another investigational drug or participation in another investigational trial
- Severe concomitant diseases (e.g. immune deficiency syndrome)
- Severe psychological disease or neurological damage without possibility to communicate
- Clinical signs of intracranial pressure
- Intracerebral hemorrhage, gliomatosis
- No severe blood count abnormalities: leukocytes < 2.000/µl, Hb <10 g/dl, thrombocytes < 100.000/µl
- No severe liver enzyme elevation (> 2-3x fold of normal)
- Ongoing reirradiation or chemotherapy (within the last 4 weeks) (irradiation of formerly non-involved fields is allowed, but not part of this study)
- Estimated life expectancy of less than 2 months
- Preexisting severe cardiac disease
- Presence of unresectable spinal metastases
- Karnofsky index < 50%
- Active infection within the last 2 weeks
- Previous infection with Human Immunodeficiency, Hepatitis C, Human T-Lymphocyte 1/2, Hepatitis B Virus, Lues, protozoan parasites, or other chronic bacterial infections.
- With regard to prevention of variant Creutzfeldt-Jakob disease the following patients have to be excluded.
- Patients receiving systemic immunosuppressive or immunoactivating substances.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active vaccination arm
All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
|
oral metronomic cyclophosphamide
resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 month overall survival
Time Frame: 6 months
|
overall survival 6 months after diagnosis of relapse
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: 12-24 months
|
overall survival
|
12-24 months
|
progression-free survival
Time Frame: 12-24 months
|
progression-free survival
|
12-24 months
|
toxicity metronomic cyclophosphamide
Time Frame: 12-24 months
|
frequency of adverse events associated with metronomic cyclophosphamide
|
12-24 months
|
toxicitiy vaccine
Time Frame: 12-24 months
|
frequency of adverse events associated with the vaccine
|
12-24 months
|
toxicity checkpoint blockade
Time Frame: 12-24 months
|
frequency of AEs/SAEs associated with Nivolumab and/or Ipilimumab
|
12-24 months
|
Treg frequency
Time Frame: 12-24 months
|
frequency of CD4+CD25+CD127- regulatory T cells under metronomic cyclophosphamide in % of CD3+
|
12-24 months
|
Treg numbers
Time Frame: 12-24 months
|
absolute numbers of CD4+CD25+CD127- regulatory T cells under metronomic cyclophosphamide per µl blood
|
12-24 months
|
T-cell response
Time Frame: 12-24 months
|
Interferon-gamma Cytotoxic T cell (CTL) assay
|
12-24 months
|
serum cytokine levels
Time Frame: 12-24 months
|
Tru Culture cytokine array
|
12-24 months
|
correlation with histopathological tumor characteristics
Time Frame: 12-24 months
|
correlation of outcome/immune response with histopathology etc.
|
12-24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Kramm Christof, MD, Children's Hospital, University Medical Center Göttingen
Publications and helpful links
General Publications
- Lohr M, Freitag B, Technau A, Krauss J, Monoranu CM, Rachor J, Lutz MB, Hagemann C, Kessler AF, Linsenmann T, Wolfl M, Ernestus RI, Engelhardt S, Gelbrich G, Schlegel PG, Eyrich M. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with Treg depletion. Cancer Immunol Immunother. 2018 Oct;67(10):1545-1558. doi: 10.1007/s00262-018-2214-0. Epub 2018 Jul 27.
- Eyrich M, Schreiber SC, Rachor J, Krauss J, Pauwels F, Hain J, Wolfl M, Lutz MB, de Vleeschouwer S, Schlegel PG, Van Gool SW. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy. 2014 Jul;16(7):946-64. doi: 10.1016/j.jcyt.2014.02.017. Epub 2014 May 13.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HIT-HGG Rez Immunovac
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Glioblastoma
-
National Cancer Institute (NCI)CompletedGlioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Untreated Childhood Brain Stem Glioma | Giant Cell Glioblastoma | Untreated Childhood Anaplastic Astrocytoma | Untreated Childhood Giant Cell Glioblastoma | Untreated Childhood Glioblastoma | Untreated Childhood Gliosarcoma | Brain Stem Glioma | Untreated... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUntreated Childhood Brain Stem Glioma | Untreated Childhood Anaplastic Astrocytoma | Untreated Childhood Anaplastic Oligodendroglioma | Untreated Childhood Giant Cell Glioblastoma | Untreated Childhood Glioblastoma | Untreated Childhood Gliomatosis Cerebri | Untreated Childhood Gliosarcoma | Untreated...United States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
Erik MittraNational Cancer Institute (NCI)TerminatedUntreated Childhood Brain Stem Glioma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma and other conditionsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedRecurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliomatosis Cerebri | Recurrent Childhood GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedChildhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood... and other conditionsUnited States, Canada
-
Sue O'DorisioNational Cancer Institute (NCI); Ride for KidsWithdrawnRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Untreated Childhood Brain Stem Glioma | Untreated Childhood Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Adult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditionsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedRecurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
Clinical Trials on depletion of regulatory T cells
-
Assistance Publique - Hôpitaux de ParisPierre and Marie Curie University; Université Paris XIICompletedHematologic Neoplasms | RelapseFrance
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative SyndromeUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompletedAutoimmune Diseases | Ulcerative ColitisGermany
-
Stanford UniversityWithdrawnCovid19 | Acute Respiratory Distress SyndromeUnited States
-
The Nordic Network For Clinical Islet TransplantationActive, not recruiting
-
King's College Hospital NHS TrustRecruiting
-
Laura JohnstonNational Institutes of Health (NIH)CompletedGraft Versus Host Disease | Allogeneic Hematopoietic Cell Transplant RecipientUnited States
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States
-
Nanjing Medical UniversityUnknown
-
Shanghai Children's Medical CenterChinese University of Hong Kong; Nanfang Hospital of Southern Medical University and other collaboratorsRecruitingRelapsed Pediatric AML | Relapsed Pediatric ALL | Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)China